Elder Pharma takes 51% in Biomeda (India)
This article was originally published in PharmAsia News
Executive Summary
Elder Pharmaceuticals has purchased a 51 percent-stake in Bulgaria's Biomeda Group for 5 million euros in an all-cash deal. Biomeda is among Bulgaria's Top 10 oral dosage formulation manufacturer and distributor. "Biomeda, is a unique acquisition of Elder and it will provide us the right entry vehicle to enter the Bulgarian market, leveraging Elder's robust EU product portfolio and impressive pipeline," Elder Pharmaceuticals director (international) Alok Saxena said in a statement. The acquisition will provide Elder access to key markets of Europe, Saxena said, and is part of Elder's move to have a foothold in major regulated global markets with specific focus on Europe, Asia-Pacific, and Latin America. (Click here for more
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.